Antimicrobial treatment of urinary tract infections in children.


Journal

Infectious diseases now
ISSN: 2666-9919
Titre abrégé: Infect Dis Now
Pays: France
ID NLM: 101775152

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 08 09 2023
accepted: 13 09 2023
medline: 5 12 2023
pubmed: 21 9 2023
entrez: 20 9 2023
Statut: ppublish

Résumé

Urinary tract infections are the most frequently proven bacterial infections in pediatrics. The treatment options proposed in this guide are based on recommendations published by the Groupe de Pathologie Infectieuse de Pédiatrique (GPIP-SFP). Except in rare situations (newborns, neutropenia, sepsis), a positive urine dipstick for leukocytes and/or nitrites should precede a urine culture examination and any antibiotic therapy. After rising steadily between 2000 and 2012, the proportion of Escherichia coli strains resistant to extended-spectrum ß-lactamases (E-ESBL) has remained stable over the last ten years (between 7% and 10% in pediatrics). However, in many cases no oral antibiotic is active on E-ESBL leading either to prolonged parenteral treatment, or to use of a non-orthodox combination such as cefixime + clavulanate. With the aim of avoiding penem antibiotics and encouraging outpatient management, this guide favors initial treatment of febrile urinary tract infections (suspected or actual E-ESBL infection), with amikacin. Amikacin remains active against the majority of E-ESBL strains. It could be prescribed as monotherapy for patients in pediatric emergency departments or otherwise hospitalized patients.

Identifiants

pubmed: 37730164
pii: S2666-9919(23)00148-3
doi: 10.1016/j.idnow.2023.104786
pii:
doi:

Substances chimiques

Amikacin 84319SGC3C
Anti-Bacterial Agents 0
Anti-Infective Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

104786

Informations de copyright

Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Fouad Madhi (F)

Université Paris Est, IMRB-GRC GEMINI, 94000 Créteil, France; Pediatric Infectious Pathology Group of the French Pediatric Society (GPIP), France; General Pediatrics Department, Centre Hospitalier Intercommunal de Créteil, Créteil, France.

Alexis Rybak (A)

Pediatric Infectious Pathology Group of the French Pediatric Society (GPIP), France; Pediatric Emergency, Hôpital Robert Debré, Paris, France.

Romain Basmaci (R)

Pediatric Infectious Pathology Group of the French Pediatric Society (GPIP), France; Department of Pediatrics, Hôpital Louis Mourier, Colombes, France.

Anne-Sophie Romain (AS)

Pediatric Infectious Pathology Group of the French Pediatric Society (GPIP), France; Pediatric Emergency, Hôpital Trousseau, Paris, France.

Andréas Werner (A)

Pediatric Infectious Pathology Group of the French Pediatric Society (GPIP), France; Outpatient Pediatrician, Villeneuve-lès-Avignon, France; Primary Care Paediatrician, Association Française de Pédiatrie Ambulatoire, France.

Sandra Biscardi (S)

Pediatric Infectious Pathology Group of the French Pediatric Society (GPIP), France; Pediatric Emergency, Centre Hospitalier Intercommunal de Créteil, Créteil, France.

François Dubos (F)

Pediatric Infectious Pathology Group of the French Pediatric Society (GPIP), France; Pediatric Emergencies & Infectious Diseases, CHRU Lille & University of Lille, Lille, France.

Albert Faye (A)

Pediatric Infectious Pathology Group of the French Pediatric Society (GPIP), France; Department of Pediatrics, Robert Debré Hospital, Paris, France.

Emmanuel Grimprel (E)

Pediatric Infectious Pathology Group of the French Pediatric Society (GPIP), France; University of Paris 6, Department of Pediatrics, Trousseau Hospital, Paris, France.

Josette Raymond (J)

Pediatric Infectious Pathology Group of the French Pediatric Society (GPIP), France; Microbiology Department, Kremlin Bicêtre Hospital, Paris.

Barbara Ros (B)

Pediatric Infectious Pathology Group of the French Pediatric Society (GPIP), France; Pediatric Emergency, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.

Robert Cohen (R)

Université Paris Est, IMRB-GRC GEMINI, 94000 Créteil, France; Pediatric Infectious Pathology Group of the French Pediatric Society (GPIP), France; Unité Court Séjour, Petits Nourrissons, Service de Néonatologie, Centre Hospitalier Intercommunal de Créteil, France; Association Clinique et Thérapeutique Infantile du Val de Marne (ACTIV), Créteil, France. Electronic address: robert.cohen@activ-france.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH